RXRB and atherosclerosis: Moreover, the in vivo experiment in the present study for the first time showed that MDM2 inhibitor JNJ-165 alleviated the development of atherosclerosis and reversed mitochondrial damage and related inflammation in this process, along with the increased RXRβ protein expression in the aorta of mice.